Last reviewed · How we verify
Etoposide, Ifosfamide, Methotrexate
This is a combination chemotherapy regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms.
This is a combination chemotherapy regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms. Used for Pediatric and adolescent cancers (lymphomas, sarcomas, and other solid tumors), High-risk or relapsed/refractory malignancies.
At a glance
| Generic name | Etoposide, Ifosfamide, Methotrexate |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Drug class | Combination chemotherapy (topoisomerase II inhibitor, alkylating agent, antimetabolite) |
| Target | DNA (topoisomerase II, DNA alkylation, dihydrofolate reductase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Etoposide is a topoisomerase II inhibitor that prevents DNA unwinding and repair. Ifosfamide is an alkylating agent that cross-links DNA strands. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, blocking nucleotide synthesis. Together, these agents target rapidly dividing cancer cells through complementary cytotoxic pathways.
Approved indications
- Pediatric and adolescent cancers (lymphomas, sarcomas, and other solid tumors)
- High-risk or relapsed/refractory malignancies
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Mucositis
- Alopecia
- Hemorrhagic cystitis (ifosfamide-related)
- Nephrotoxicity
- Neurotoxicity
Key clinical trials
- CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL (PHASE3)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PHASE3)
- Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma (PHASE2)
- Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (PHASE2)
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: